402 related articles for article (PubMed ID: 31407119)
21. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
Patil MB; Ghode P; Joshi P
Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
[TBL] [Abstract][Full Text] [Related]
22. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
[TBL] [Abstract][Full Text] [Related]
23. [Experience with tafamidis in a patient with transthyretin amyloidosis].
Nasonova SN; Zhirov IV; Magomedov MM; Saidova MA; Osmolovskaya YF; Tereschenko SN
Kardiologiia; 2020 Jan; 60(3):155-160. PubMed ID: 32375630
[TBL] [Abstract][Full Text] [Related]
24. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
Bézard M; Kharoubi M; Galat A; Poullot E; Guendouz S; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Gendre T; Audard V; El Karoui K; Canoui-Poitrine F; Zaroui A; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Damy T
Eur J Heart Fail; 2021 Feb; 23(2):264-274. PubMed ID: 33094885
[TBL] [Abstract][Full Text] [Related]
25. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Rozenbaum MH; Garcia A; Grima D; Tran D; Bhambri R; Stewart M; Li B; Heeg B; Postma M; Masri A
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):529-538. PubMed ID: 33895806
[TBL] [Abstract][Full Text] [Related]
26. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
Gonzalez-Duarte A
Clin Auton Res; 2019 Apr; 29(2):245-251. PubMed ID: 29511897
[TBL] [Abstract][Full Text] [Related]
27. Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy.
Gendre T; Planté-Bordeneuve V
Clin Auton Res; 2019 Sep; 29(Suppl 1):25-31. PubMed ID: 31506870
[TBL] [Abstract][Full Text] [Related]
28. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
Sekijima Y
Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
Kazi DS; Bellows BK; Baron SJ; Shen C; Cohen DJ; Spertus JA; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
Circulation; 2020 Apr; 141(15):1214-1224. PubMed ID: 32078382
[TBL] [Abstract][Full Text] [Related]
30. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
Samjoo IA; Salvo EM; Tran D; Amass L; Stewart M; Cameron C
Curr Med Res Opin; 2020 May; 36(5):799-808. PubMed ID: 32011182
[No Abstract] [Full Text] [Related]
31. Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients.
Conceição I; Miranda B; Castro J; de Carvalho M
Eur J Neurol; 2018 Nov; 25(11):1320-e115. PubMed ID: 29924456
[TBL] [Abstract][Full Text] [Related]
32. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
35. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Sultan MB; Maurer MS
Future Cardiol; 2022 Mar; 18(3):165-172. PubMed ID: 34779246
[TBL] [Abstract][Full Text] [Related]
36. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
Amass L; Li H; Gundapaneni BK; Schwartz JH; Keohane DJ
Orphanet J Rare Dis; 2018 Dec; 13(1):225. PubMed ID: 30558645
[TBL] [Abstract][Full Text] [Related]
37. [Neurological manifestations of ATTR amyloidosis].
Pernice HF; Hahn K
Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
[TBL] [Abstract][Full Text] [Related]
38. Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS).
González-Duarte A; Barroso F; Mundayat R; Shapiro B
Auton Neurosci; 2019 Dec; 222():102590. PubMed ID: 31726319
[TBL] [Abstract][Full Text] [Related]
39. [What gnaws at the heart and gets on the nerves].
Kristen AV
Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
[TBL] [Abstract][Full Text] [Related]
40. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
